Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised Trial Investigating the Effect on Biochemical (PSA) Control and Survival of Different Durations of Adjuvant Androgen Deprivation in Association With Definitive Radiation Treatment for Localised Carcinoma of the Prostate.

Trial Profile

A Randomised Trial Investigating the Effect on Biochemical (PSA) Control and Survival of Different Durations of Adjuvant Androgen Deprivation in Association With Definitive Radiation Treatment for Localised Carcinoma of the Prostate.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Zoledronic acid (Primary) ; Leuprorelin
  • Indications Bone metastases; Fracture; Osteoporosis; Prostate cancer
  • Focus Adverse reactions; Registrational
  • Acronyms RADAR
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 10 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 05 Sep 2017 Results (n=100) of secondary analysis assessing effect of prior exposure to androgen deprivation therapy, in men with prostate cancer undertaking a yearlong exercise program, on body composition and muscle performance published in the BJU International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top